Justin Cooper

WASHINGTON — SGLT2 inhibitors can reduce the need for urate-lowering and flare therapies, and lower the odds of gout-centric medical visits, in

WASHINGTON — Pain in patients scheduled for total knee arthroplasty demonstrates no relation to physical activity, suggesting pain relief alone may

WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.

WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant

WASHINGTON — Despite answering 78% of rheumatology questions correctly, besting two other popular large language models, GPT-4 nonetheless introduced the “possibility of harm” in up to 20% of its responses, according to data.

WASHINGTON — Rising rates of ACR20 response in the placebo arms of rheumatoid arthritis trials may be related to increasingly globalized recruitment patterns, according to data presented at ACR Convergence 2024.

WASHINGTON — High rates of premature mortality from rheumatoid arthritis among Native American populations have seen no change in the past 20 years, while other races have demonstrated improving trends, according to data. “Many people with rheumatoid arthritis die at younger ages from cardiovascular, respiratory, cancer and infectious causes,” Parmita Das, of the University of

WASHINGTON — Patients with lupus and type 2 diabetes who receive glucagon-like peptide-1 receptor agonists demonstrate a lower risk for cardiac

WASHINGTON — A drug combining elsubrutinib with upadacitinib led to lower disease activity for up to 104 weeks in patients with moderately to severely

WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public